From Concept To Commercial Reality: Successful Upscaling Strategies For Viral Vector Manufacturing

By Pirjo Merilahti, Ph.D., Technology Manager, Gene Therapy Manufacturing & Development at 3PBIOVIAN

As gene therapy programs move toward late‑stage development and commercialization, scaling viral vector manufacturing becomes one of the most complex inflection points. Unlike traditional biologics, viral vector processes are highly sensitive to early design decisions that can either support smooth scale‑up or create downstream constraints.

Embedding scalability from the outset is critical, with predictive downscale models, scale‑relevant parameters, and execution strategies aligned to future GMP conditions playing a central role. Practical challenges include managing extended seed trains, navigating transitions between adherent and suspension systems, and defining infection and harvest strategies that remain robust at larger scales.

Mid‑scale bioreactors serve as an essential bridge between bench‑scale optimization and large‑scale manufacturing, allowing teams to validate robustness before committing to full GMP production. Integrating development, manufacturing, and quality perspectives early helps reduce risk, improve reproducibility, and support more confident progression from concept to commercial reality.